icon-folder.gif   Conference Reports for NATAP  
 
  EASL 44th Annual Meeting
April 22-26, 2009
Copenhagen, Denmark
Back grey_arrow_rt.gif
 
 
 
Entecavir Maintains a High Genetic Barrier to HBV Resistance Through 6 Years in Naive Patients
 
 
  EASL April 23-26 2009 Copenhagen Denmark
Reported by Jules Levin, NATAP
 
D.J. Tenney1, K.A. Pokorowski1, R.E. Rose1, C.J. Baldick1, B.J. Eggers1, J. Fang1, M.J. Wichroski1, U. Diva1, D. Xu1, R.B. Wilber1, H. Brett-Smith1 & U.H. Iloeje1 1Research and Development, Bristol-Myers Squibb Company, United States
 
Oral Presentations
 
Session Title: Parallel Session 2: HEPATITIS B VIRUS THERAPY
Presentation Date: Apr 23, 2009
 
ENTECAVIR MAINTAINS A HIGH GENETIC BARRIER TO HBV RESISTANCE THROUGH 6 YEARS IN NAIVE PATIENTS
 
D.J. Tenney, K.A. Pokornowski, R.E. Rose, C.J. Baldick, B.J. Eggers, J. Fang, M.J. Wichroski, U.A. Diva, D. Xu, R.B. Wilber, H. Brett-Smith, U.H. Iloeje Research and Development, Bristol-Myers Squibb Company, Wallingford, CT, USA
 
Background/ aims: Entecavir (ETV) provides both potent viral suppression and a high genetic barrier to resistance. As a result, in nucleoside-naive patients, ETV resistance (ETVr) was rare through 5 years. The barrier to resistance in lamivudine (LVD)-refractory patients is reduced.
 
Methods: All patients receiving continuous therapy in registrational trials were monitored for resistance through year 6. Sequencing was performed on serum samples with detectable HBV DNA (≥300 copies/mL) at each cross-sectional end-of-year analysis, or with viral breakthrough at anytime, or at discontinuation from study with detectable HBV DNA. Cumulative probabilities of resistance were determined through year 6.
 
Results: In years 1 through 6, respectively, 663, 278, 149, 120, 108 and 99 nucleoside-naive patients were treated and monitored, with 94% in year 6 having HBV DNA < 300 copies/mL. No patient in year 6 showed emerging ETVr at T184, S202 or M250 ± LVD resistance (LVDr) M204I/V±L180M. The cumulative probability of genotypic ETVr in nucleoside-naive patients remained at 1.2% through 6 years. Among LVD-refractory patients treated with ETV, 187, 146, 80, 52, 33 and 29 were monitored in years 1 through 6, respectively. The cumulative probabilities of genotypic ETVr at years 1 through 6 were 6%, 15%, 36%, 47%, 51%, and 57% respectively, and of virological breakthrough with ETVr was 50% through year 6. Among the 74 LVD-refractory patients who achieved undetectable HBV DNA on ETV, 5 subsequently developed ETVr.
 
Conclusions: ETVr remains rare (1.2%) in nucleoside-naive patients through 6 years. LVDr HBV has a reduced resistance barrier to ETV, and patients with LVDr HBV may benefit from add-on or combination therapy.

Factors-1.gif

ETV-2.gif

Flow-3.gif

acrpss-4.gif

Ref-5.gif

Naive-6.gif

squib-7.gif